Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Sep 25, 2026
Why Is Tradr 2X Long AXTI Daily ETF (AXTX) ETF Up +10.84% Today?

Why Is Tradr 2X Long AXTI Daily ETF (AXTX) ETF Up +10.84% Today?

Key Takeaways

  • AXTX climbed 10.84% to $37.21, up $3.64 from the prior close of $33.57.
  • The move was driven by a sharp rally in the fund's underlying security, AXT, Inc. (AXTI), which rose more than 5% intraday.
  • As a 2x leveraged single-stock ETF, AXTX is designed to deliver roughly twice the daily return of AXTI, amplifying the session's gains.
  • Primary catalysts include surging demand for AI data-center optical connectivity and compound semiconductor substrates, including indium phosphide (InP) and gallium arsenide (GaAs).
  • Supportive factors include AXTI's recent S&P 600 inclusion, positive analyst commentary on co-packaged optics, and strong quarterly results.
  • Investors are watching AI-infrastructure demand, capacity expansion, and the elevated volatility and leverage decay inherent to leveraged ETFs.

Opening Summary

The Tradr 2X Long AXTI Daily ETF (AXTX) surged 10.84% in Thursday's session, rising $3.64 to $37.21 from a prior close of $33.57. The fund seeks daily investment results, before fees and expenses, equal to 200% of the daily performance of AXT, Inc. (AXTI), a materials-science company that manufactures compound semiconductor wafer substrates. Because AXTI advanced more than 5% on the day, the leveraged structure of AXTX converted that gain into a double-digit move for the ETF.

What Drove the ETF Move Today

Underlying Security Surge and Leverage Amplification

The dominant driver of AXTX's advance was a broad rally in AXT, Inc., which climbed more than 5% intraday as investors continued to bid up shares tied to artificial-intelligence infrastructure. Because AXTX is a single-stock leveraged product, its daily return is engineered to move at roughly twice the magnitude of its underlying holding. This mechanical amplification, rather than any independent news specific to the ETF, explains why a mid-single-digit move in AXTI translated into an ETF rally of more than 10%.

AI Data-Center Optical Demand and Compound Semiconductor Momentum

The broader narrative behind the move is accelerating demand for the compound semiconductor materials at the center of AI networking. AXT produces indium phosphide and gallium arsenide substrates used in high-speed optical transceivers, fiber-optic connectivity, and data-center links. As AI data centers deploy 800G and 1.6T optical transceivers and move toward co-packaged optics, demand for InP substrates has outpaced supply. The company has reported record indium phosphide revenue and a backlog exceeding $100 million, reinforcing the sector-driven momentum behind the stock and, by extension, the ETF.

Index Inclusion and Analyst Support

Investor sentiment was further supported by AXT's recent addition to the S&P 600, an event that typically prompts institutional and index-tracking funds to build positions. The company has also been highlighted by sell-side analysts as a key beneficiary of the accelerating co-packaged optics market, alongside names such as Coherent Corp. (COHR) and Lumentum Holdings (LITE). Long-term supply agreements with Casela, Coherent, and Lumentum have added revenue visibility, supporting the bullish tone in the underlying shares.

Which Holdings Contributed Most

As a leveraged single-stock ETF, AXTX does not hold a diversified basket of securities. Its performance is tied directly to the daily movement of AXT, Inc., generally achieved through swaps and other financial instruments that seek 2x exposure. Consequently, essentially all of today's move is attributable to the performance of AXTI itself. The company's exposure to indium phosphide substrates for AI data-center connectivity, gallium arsenide for optoelectronic applications, and germanium for other specialty uses makes it a concentrated, high-beta play on the AI and optical-networking buildout.

Market Context and Trading Activity

The ETF's advance occurred amid a constructive tone across semiconductor and AI-infrastructure names, with compound-semiconductor and optical-component suppliers among the session's notable gainers. Trading in AXTI remained elevated relative to recent sessions, consistent with sustained institutional interest. The move in AXTX was directionally consistent with the underlying security but larger in magnitude due to leverage. Technically, the rebound follows a period of choppy trading, and the underlying stock has reclaimed levels above several near-term moving averages, reflecting renewed risk-on appetite in the AI-hardware complex.

What Comes Next for AXTX

The near-term outlook for AXTX is tied to the trajectory of AI data-center capital spending and optical-connectivity demand. Key factors to monitor include indium phosphide supply and pricing, the pace of capacity expansion, and whether hyperscalers sustain their buildout of 800G and 1.6T networking. Risks are meaningful: leveraged ETFs are designed for short-term trading, and daily rebalancing can produce returns that diverge from long-term performance of the underlying asset, particularly in volatile markets. Additional considerations include AXT's elevated valuation, its manufacturing footprint in China and related export-control exposure, and growing competition from vertically integrated customers such as Coherent and Lumentum. Investors should watch for semiconductor demand cyclicality, order volatility, and any shift in AI-infrastructure sentiment.

Trending AI Robots

Tickeron's Trending AI Robots page highlights a curated selection of AI-driven trading bots that are currently demonstrating the strongest performance under prevailing market conditions. Tickeron offers hundreds of AI trading bots covering thousands of tickers, each varying by strategy, timeframe, performance metrics, and traded symbols. Only the top performers are featured in this section, helping traders identify strategies that are working right now. Explore the Trending AI Robots to discover automated approaches that may complement your market analysis.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: AXTX

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


Momentum Indicator for AXTX turns positive, indicating new upward trend

AXTX saw its Momentum Indicator move above the 0 level on September 16, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 3 similar instances where the indicator turned positive. In 3 of the 3 cases, the stock moved higher in the following days. The odds of a move higher are at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Moving Average Convergence Divergence (MACD) for AXTX just turned positive on September 09, 2026. Looking at past instances where AXTX's MACD turned positive, the stock continued to rise in 1 of 1 cases over the following month. The odds of a continued upward trend are 90%.

AXTX moved above its 50-day moving average on September 21, 2026 date and that indicates a change from a downward trend to an upward trend.

Following a +36.58% 3-day Advance, the price is estimated to grow further. Considering data from situations where AXTX advanced for three days, in 18 of 21 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.

Bearish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where AXTX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

AXTX broke above its upper Bollinger Band on September 21, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for AXTX entered a downward trend on September 15, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Industry description

The investment seeks daily investment results, before fees and expenses, that correspond to two times (200%) the daily performance of the common shares of AXT, Inc. Under normal market circumstances, the fund will maintain at least 80% exposure to financial instruments that provide two times leveraged exposure to the daily performance of AXTI. It is non-diversified.
View a ticker or compare two or three
AXTX
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Category Trading

Category
Trading--Leveraged Equity
Address
Investment Managers Series Trust II803 West Michigan StreetMilwaukee
Phone
(414) 299-2295
Web
N/A
Interact to see
Advertisement
INSM shares are surging approximately +10% in premarket trading on Monday, March 23, 2026, from a prior close of $136.00, placing the premarket price near $149.60. The primary catalyst is the release of positive topline results from the Phase 3 ENCORE trial of ARIKAYCE® in patients with newly diagnosed or recurrent MAC (Mycobacterium avium complex) lung disease — a readout Insmed had flagged as expected in "March or April 2026".
CF shares are trading approximately -6% lower in Monday's premarket session, dropping from a Friday close of $124.90 to approximately $117.41. Primary catalyst: President Trump announced a five-day pause on strikes against Iranian energy infrastructure following "very good" diplomatic signals, triggering a sharp unwind of the geopolitical risk premium embedded in fertilizer stocks.
APGE shares surged approximately 16% in premarket trading on March 23, 2026, after the company announced positive 52-week data from Part A of its Phase 2 APEX clinical trial. The primary catalyst is a highly anticipated clinical readout showing that zumilokibart (APG777) delivered durable and deepening responses in patients with moderate-to-severe atopic dermatitis at both every 3-month and 6-month dosing intervals.
Shares of VALN are plummeting approximately 35% in Monday's session, from a Friday close of $10.66 to roughly $6.93, in heavy volume trading. The primary catalyst is the release of Phase 3 VALOR trial topline results for Valneva's Lyme disease vaccine candidate, co-developed with PFE (Pfizer) — results that showed strong clinical efficacy but failed to meet the pre-determined statistical criterion for the primary endpoint.
AXTI is surging approximately +11.00% in Monday's session, trading near $60.21, up from a prior closing price of $54.24. The move extends the stock's post-earnings rally that began last Thursday when shares jumped more than 19% following AXT's Q4 2025 results.
Tower Semiconductor (TSEM) shares are surging approximately +10% intraday on Monday, March 23, trading around $180, up from the previous close of $163.63 on March 20, 2026. The primary catalyst is the opening day of APEC 2026 in San Antonio, Texas, where Tower Semiconductor is presenting its newly unveiled Gen3 BCD power management platform designed to address escalating AI data center power demands.
CD is indicated down about 17% in premarket trading after the latest completed session, pointing to a sharp negative market reaction heading into the open. The stock’s weakness comes against a backdrop of lingering uncertainty following its privatization and delisting process from Nasdaq, which has left limited liquidity and a thinner news flow around the name.
SEDG is indicated down roughly 9% in premarket trading, following a strong advance in the prior regular session. The pullback comes after shares rallied on optimism around new product launches and an analyst upgrade, leaving the stock vulnerable to profit-taking and volatility.
NTGR shares surged approximately 11% in premarket trading on March 24, 2026, building on a roughly 20% overnight jump in the prior session. The primary catalyst is a landmark Federal Communications Commission (FCC) ruling that prohibits all imports of consumer routers manufactured overseas, citing national security concerns.
ANNA is surging approximately +20.00% in Tuesday's premarket session, rebounding sharply from Monday's -22.84% decline. The primary catalyst remains the ongoing U.S.-Iran military conflict, which disrupted Qatari LNG exports and drove European benchmark natural gas prices to multi-year highs.
Concentrix Corporation (CNXC) shares are falling approximately 11% in Tuesday's premarket session after the company released its fiscal Q1 2026 earnings report before market open. Adjusted diluted EPS came in at $2.61, missing the Wall Street consensus estimate of approximately $2.64.
Shares of Karyopharm Therapeutics (KPTI) are trading approximately 12% lower in Tuesday's premarket session, with the previous close at $7.63. The primary catalyst is the March 24 release of topline Phase 3 SENTRY trial data, in which the company met only one of two co-primary endpoints.
IBRX shares are down approximately 23% in Tuesday's session, trading near $7.24 after closing at $9.40 on Monday, March 23. The sharp decline follows an 11%+ surge in the prior session, with profit-taking and valuation pressure cited as primary triggers.
Shares of Circle Internet Group (CRCL) are down approximately 9% in Tuesday morning trading, extending a pullback from recent multi-month highs above $126. The primary catalyst appears to be a broad crypto-sector risk-off wave, with Bitcoin sliding below $69,000 and the Fear & Greed Index dropping to extreme fear territory.
ALM shares are indicated down about 11% in early Tuesday trading after closing the prior session at $16.93. The move comes after a powerful multi‑month rally that took the stock from below $3 to an intraday high of $22.55 earlier in March, leaving it vulnerable to profit-taking and volatility.​
LUNR shares are indicated down about 7% in Tuesday premarket trading after closing the last regular session at $20.31. The pullback follows a powerful rally driven by strong 2026 revenue guidance of $900 million–$1 billion and upbeat analyst commentary, including price target hikes and buy ratings.
MAZE shares are trading approximately 27% lower in premarket on March 25, 2026, after the company reported its highly anticipated Phase 2 HORIZON trial topline data for lead drug candidate MZE829. The catalyst is a dual announcement: Phase 2 clinical data for MZE829 in APOL1-mediated kidney disease (AMKD) alongside Q4 and full-year 2025 financial results.
ARM shares surged approximately +10% in premarket trading on March 25, 2026, hitting $148.6 from a prior close of approximately $135. The primary catalyst is Arm's historic strategic pivot: the company announced it will begin selling its own self-developed AGI CPU chips, breaking its decades-long "IP licensing only" business model.
Shares of Enliven Therapeutics (ELVN) are surging approximately +15% in premarket trading on March 25, 2026, driven by renewed investor enthusiasm around the company's advancing clinical program for ELVN-001 in chronic myeloid leukemia (CML). The stock's prior closing price on March 24, 2026 was $31.15, placing the premarket indicated price near $35.82.
AVXL shares are down approximately 29% in premarket trading on Wednesday, March 25, 2026, falling to roughly $2.97 from the prior close of $4.19. The primary catalyst is Anavex's formal withdrawal of its marketing authorization application (MAA) for blarcamesine from the European Union, announced in the early hours of March 25, 2026.